Immunovant director receives new stock awards
Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation.
Rhea-AI Filing Summary
Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation. He was granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. He also received 13,880 shares of common stock in the form of restricted stock units. These RSUs and the option shares will vest on April 1, 2027, if he continues service with the company through that date. Following these awards, he holds 116,731 common shares directly and 20,000 common shares indirectly through a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 20,941 shares
Grant/Award
3 txns
Insider
Pande Atul
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,061 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 13,880 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 7,061 contracts (Direct);
Common Stock — 116,731 shares (Direct);
Common Stock — 20,000 shares (Indirect, By Trust)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
Stock options granted: 7,061 options
Option exercise price: $24.61 per share
Option expiration: April 7, 2036
+4 more
7 metrics
Stock options granted
7,061 options
Grant on April 7, 2026 to purchase common stock
Option exercise price
$24.61 per share
Exercise price for 7,061 stock options
Option expiration
April 7, 2036
Expiry date of granted stock options
RSUs granted
13,880 shares
Restricted stock units granted April 7, 2026
Vesting date
April 1, 2027
Vesting for RSUs and option shares, subject to service
Direct common shares after grant
116,731 shares
Direct Immunovant common stock ownership post-award
Indirect common shares by trust
20,000 shares
Indirect holdings classified as “By Trust”
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Rule 409A, Stock Option (right to buy)
4 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Rule 409A regulatory
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Immunovant (IMVT) director Atul Pande report?
Director Atul Pande reported equity awards, not market trades. He received 7,061 stock options and 13,880 restricted stock units in Immunovant common stock as part of compensation, increasing his direct and indirect ownership positions.
How many Immunovant (IMVT) stock options were granted to Atul Pande?
He was granted stock options for 7,061 shares of Immunovant common stock. These options have an exercise price of $24.61 per share and expire on April 7, 2036, with vesting tied to continued service through April 1, 2027.
What restricted stock unit (RSU) award did Atul Pande receive from Immunovant (IMVT)?
He received 13,880 restricted stock units under Immunovant’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and will vest in full on April 1, 2027, assuming his continuous service with the company.
When do Atul Pande’s new Immunovant (IMVT) equity awards vest?
Both the 13,880 restricted stock units and the 7,061 option shares are scheduled to vest on April 1, 2027. Vesting requires that Atul Pande remain in continuous service with Immunovant through that date under the plan terms.
Were these Immunovant (IMVT) insider transactions open-market purchases or sales?
They were not open-market trades. The filing shows grant or award acquisitions: stock options and restricted stock units granted as compensation, with no reported buying or selling of shares on the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
